Journal profile · Biotechnology & Applied Microbiology
Cytotherapy
ISSN 1465-3249 · eISSN 1477-2566 · Elsevier Inc. · NORWAY · Bimonthly · Founded 1999
Cytotherapy: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 4.44; hybrid open access; APC about USD 3,300; median 92 days to acceptance (95 articles, last 24 months); community-reported acceptance: fairly easy; 755 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Cytotherapy is published by Elsevier Inc. and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Mesenchymal stem cell research, CAR-T cell therapy research and Hematopoietic Stem Cell Transplantation, together about 35.5% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Cytotherapy, the official journal of the International Society for Cell & Gene Therapy (ISCT), publishes novel and innovative results from high quality scientific and clinical studies in the fields of cell, gene, and extracellular vesicle therapy.Cytotherapy considers manuscripts exploring the following topics:Development and/or characterization of novel gene therapies and cell and/or EV-based therapeuticsDesign of novel therapeutic approaches employing cell/EV/gene productsScientific mechanisms of action of cell/EV/gene therapies in relevant cell-based and pre-clinical modelsScientific mechanisms of action of toxicities attributable to cell/EV/gene therapiesIdentification of novel biomarkers that predict the potency of cell/EV/gene therapies and/or stratify patients based on response ratesEarly and late phase clinical studies evaluating the safety and efficacy of cell/EV/gene therapiesImportant advances in cell/EV/gene-based product manufacturing and validationGlobal/regional regulatory practices that impact the authorized use and/or regulatory approval of cell/EV and gene therapiesCytotherapy does not publish manuscripts on the following topics:Case studies unless they are of unusual significance to the fieldBasic/translational studies exploring the role of lncRNAs, circRNAs, and miRNAs in disease pathophysiologyFundamental scientific studies of normal or pathological processesStudies describing signaling pathways implicated in cancer
From the journal's Aims & Scope
Research area (LetPub): Biotechnology & Applied Microbiology
Editor-in-chief Edwin M. HorwitzPublisher website
Editorial board by country: 1 in mainland China (about 1%); most named United States 48, Australia 8, Spain 7, Canada 7, United Kingdom 3 (96 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Mesenchymal stem cell researchMedicine16.8%
- CAR-T cell therapy researchMedicine12%
- Hematopoietic Stem Cell TransplantationMedicine6.6%
- Tissue Engineering and Regenerative MedicineMedicine5.6%
- Pluripotent Stem Cells ResearchBiochemistry, Genetics and Molecular Biology4.6%
- Immune Cell Function and InteractionImmunology and Microbiology4.5%
- Diverse Scientific and Economic StudiesEconomics, Econometrics and Finance4.4%
- Biomedical Ethics and RegulationMedicine4.1%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Biotechnology & Applied Microbiology | Zone 3 |
| Minor | Hematology | Zone 3 |
| Minor | Cell & Tissue Engineering | Zone 4 |
| Minor | Cell Biology | Zone 4 |
| Minor | Medicine, Research & Experimental | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Cell & Tissue Engineering | Zone 3 |
| Minor | Biotechnology & Applied Microbiology | Zone 3 |
| Minor | Cell Biology | Zone 3 |
| Minor | Hematology | Zone 3 |
| Minor | Medicine, Research & Experimental | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Biotechnology & Applied Microbiology | Zone 3 |
| Minor | Cell Biology | Zone 3 |
| Minor | Hematology | Zone 3 |
| Minor | Medicine, Research & Experimental | Zone 3 |
| Minor | Cell & Tissue Engineering | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
PubMedPublisher website
Other: Crossref
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 4.44LetPub ·
- Impact factor (publisher)
- 4.5Publisher website ·
- CiteScore 2026-06
- 6.4LetPub ·
- CiteScore (publisher)
- 6.4Publisher website ·
- SJR 2026-06
- 1.25LetPub ·
- SNIP 2026-06
- 0.85LetPub ·
- h-index
- 76LetPub ·
- h-index
- 128OpenAlex ·
- i10-index
- 2,018OpenAlex ·
- 2-year mean citedness
- 1.1OpenAlex ·
- Self-citation rate
- 6.7%LetPub ·
- Share of gold OA articles
- 33.33%LetPub ·
Volume
- Articles per year
- 144LetPub ·
Articles by year OpenAlex count · 10,029 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 793 | 78 | 50 |
| 2025 | 755 | 95 | 753 |
| 2024 | 780 | 134 | 1,766 |
| 2023 | 783 | 119 | 1,887 |
| 2022 | 663 | 95 | 2,057 |
| 2021 | 656 | 78 | 2,439 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
92 daysMedian, submission to acceptance · P25–P75 65 days – 135 days
- Acceptance to online
- median 4 days (95 articles)
- Submission to online
- median 95 days
- Sample
- 95 articles with submission and acceptance dates (324 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 4–8 weeksLetPub ·
- Average acceptance (community reports)
- Fairly easyLetPub ·
- Submission to first decision
- 3 daysPublisher website ·
- First decision after review
- 31 daysPublisher website ·
- Submission to acceptance
- 91 daysPublisher website ·
- Peer review
- Single anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 3,300 / EUR 3,090 / GBP 2,640 / JPY 409,300 | — | — | |
| Publisher website | USD 3,500 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
Other charges and waivers (author guidelines)
- Page charges
- USD 650
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Article types accepted8, with length limits
- breviaBrevia: are very short reports describing a single finding of sufficient importance to merit publication.Length not stated
- full-length articlesFull-Length Articles: should not exceed 6000 words excluding references (usually less than 50).Typically we allow up to 8 figures and 6 tables.Length not stated
- letters to the editorsLetters to the editors: A letter regarding a recent paper (within 3 issues) will be evaluated by the editors and, if accepted, will be forwarded to the authors …Length not stated
- perspectivemmissioning Editor prior to submission. Perspectives: should be 2000-6000 words with up to 4 display items. The content should be the authomain text ≤ 6,000 words
- perspectivesPerspectives: should be 2000-6000 words with up to 4 display items.Length not stated
- review articleing more data as supplementary figures. Review Articles: should be 4000-10,000 words with up to 8 display items (figures, schema, tables). The cmain text ≤ 10,000 words
- review articlesReview Articles: should be 4000-10,000 words with up to 8 display items (figures, schema, tables).Length not stated
- short reportsShort Reports: should not exceed 3000 words excluding references; they may contain up to 3 figures or tables.Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, License & copyright, Open access, Peer review, Preprints
- AI use Declaration of generative AI in scientific writing
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
Source ↗Publisher website ·- Authorship Authorship
All authors should have made substantial contributions to all of the following: (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data, (2) drafting the article or revising it critically for important intellectual content, (3) final approval of the version to be submitted.
Source ↗Publisher website ·- Conflicts of interest Declaration of interest
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential competing interests include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. Authors must disclose any interests in two places:…
Source ↗Publisher website ·- License & copyright Copyright
Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (see more information on this). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.Subscribers may reproduce tables of contents or prepare lists of articles includ…
Source ↗Publisher website ·- Open access Open access
Please visit our Open Access page for more information about open access publishing in this journal.
Source ↗Publisher website ·- Peer review Peer review
Single anonymized review process Model summary
This journal operates a single anonymized review process. All contributions will be initially assessed by the editor for suitability for the journal. Papers deemed suitable are then typically sent to a minimum of two independent expert reviewers to assess the scientific quality of the paper. The Editor is responsible for the final decision regarding acceptance or rejection of articles. The Editor'…
Source ↗Publisher website ·- Preprints Preprint references
Where a preprint has subsequently become available as a peer-reviewed publication, the formal publication should be used as the reference. If there are preprints that are central to your work or that cover crucial developments in the topic, but are not yet formally published, these may be referenced. Preprints should be clearly marked as such, for example by including the word preprint, or the nam…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Elsevier Inc.
- Country or region
- NORWAY
- Language
- English
- Frequency
- Bimonthly
- Founded
- 1999
- ISSN
- 1465-3249
- Electronic ISSN
- 1477-2566
- Society / sponsor
- International Society for Cell & Gene Therapy
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Cytotherapy
What CAS zone is Cytotherapy in?
In the 2025 upgraded edition of the CAS Journal Ranking, Cytotherapy is in Zone 3 of Medicine, and in Zone 3 of the minor category Biotechnology & Applied Microbiology / Hematology / Cell & Tissue Engineering / Cell Biology / Medicine, Research & Experimental. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Cytotherapy?
The latest impact factor listed by LetPub is 4.44; CiteScore 6.4, h-index 128.
How long does peer review take at Cytotherapy?
Based on the dates recorded on 95 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 92 days (interquartile range 65–135 days); authors report an average review time of 4–8 weeks; the community-reported acceptance is “Fairly easy”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Cytotherapy based?
Of the 96 board members whose country the journal's board page names, 1 (about 1%) are in mainland China; the countries named most often are United States (48), Australia (8) and Spain (7). Counted from the institutions listed on the board page; for reference only.
Which databases index Cytotherapy?
According to LetPub and DOAJ records, Cytotherapy is indexed in SCIE and Scopus. The journal's website also lists PubMed; that list has not been checked against each database.
Is Cytotherapy open access, and what is the APC?
Cytotherapy is a hybrid journal. For open-access publication: APC about USD 3,300.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .